{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:44:22Z","timestamp":1787049862170,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.juro.2011.11.101","type":"journal-article","created":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T06:32:23Z","timestamp":1329201143000},"page":"1195-1199","source":"Crossref","is-referenced-by-count":31,"title":["Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer"],"prefix":"10.1097","volume":"187","author":[{"given":"K.","family":"Hendricksen","sequence":"first","affiliation":[{"name":"Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.B.","family":"Cornel","sequence":"additional","affiliation":[{"name":"Department of Urology, Twente Hospital Group, Hengelo, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"de Reijke","sequence":"additional","affiliation":[{"name":"Department of Urology, Academic Medical Centre, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.","family":"Arentsen","sequence":"additional","affiliation":[{"name":"Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chawla","sequence":"additional","affiliation":[{"name":"Spectrum Pharmaceuticals, Inc., Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Witjes","sequence":"additional","affiliation":[{"name":"Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2011.11.101_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.juro.2011.11.101_bib2","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.11.101_bib3","series-title":"European Association of Urology Guidelines, 2011","first-page":"1","article-title":"Guidelines on non-muscle invasive bladder cancer (TaT1 and CIS)","author":"Babjuk","year":"2011"},{"key":"10.1016\/j.juro.2011.11.101_bib4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2011.11.101_bib5","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/13543784.17.7.1085","article-title":"Apaziquone for non-muscle invasive bladder cancer: a critical review","volume":"17","author":"Witjes","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.juro.2011.11.101_bib6","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.ju.0000146274.85012.e1","article-title":"Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study","volume":"173","author":"van der Heijden","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.11.101_bib7","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.juro.2006.06.007","article-title":"Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response","volume":"176","author":"van der Heijden","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.11.101_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00345-009-0382-4","article-title":"Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer","volume":"27","author":"Hendricksen","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.juro.2011.11.101_bib9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9","article-title":"TNM Classification of Malignant Tumors, fifth edition (1997)","volume":"80","author":"Sobin","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2011.11.101_bib10","series-title":"International Classification of Tumors 10","article-title":"Histological typing of urinary bladder tumours","author":"Mostofi","year":"1973"},{"key":"10.1016\/j.juro.2011.11.101_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","article-title":"Guidelines on bladder cancer","volume":"41","author":"Oosterlinck","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2011.11.101_bib12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/rcm.3387","volume":"22","author":"Vainchtein","year":"2008","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.juro.2011.11.101_bib13","doi-asserted-by":"crossref","first-page":"438","DOI":"10.5694\/j.1326-5377.2003.tb05627.x","article-title":"Inclusion of patients in clinical trial analysis: the intention-to-treat principle","volume":"179","author":"Heritier","year":"2003","journal-title":"Med J Aust"},{"key":"10.1016\/j.juro.2011.11.101_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.juro.2007.08.166","article-title":"A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences","volume":"179","author":"Berrum-Svennung","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.11.101_bib15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","article-title":"Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection?","volume":"55","author":"Gudj\u00f3nsson","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2011.11.101_bib16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.eururo.2007.12.033","article-title":"Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer","volume":"53","author":"Hendricksen","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2011.11.101_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2009.03.074","article-title":"An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: has the evidence changed?","volume":"56","author":"Sylvester","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2011.11.101_bib18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy-associated events","volume":"7","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.juro.2011.11.101_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0094-0143(21)00419-5","article-title":"Complications of intravesical chemotherapy","volume":"19","author":"Thrasher","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.juro.2011.11.101_bib20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"van der Meijden","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.11.101_bib21","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0022-5347(01)66224-4","article-title":"The quality of life during intravesical bacillus Calmette-Guerin therapy","volume":"155","author":"Bohle","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.11.101_bib22","first-page":"29","article-title":"Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions)","volume":"378","author":"Bouffioux","year":"1992","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.juro.2011.11.101_bib23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0360-3016(92)90509-G","article-title":"Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents","volume":"22","author":"Workman","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2011.11.101_bib24","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/0959-8049(96)00120-7","article-title":"Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9","volume":"32A","author":"McLeod","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.juro.2011.11.101_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/bjc.1992.73","article-title":"In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity","volume":"65","author":"Phillips","year":"1992","journal-title":"Br J Cancer"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002253471105779X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002253471105779X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2011.11.101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T22:25:53Z","timestamp":1651184753000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2011.11.101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1016\/j.juro.2011.11.101"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2011.11.101","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}